Claims
- 1. An isolated polynucleotide that remains hybridized in 0.1×SSC at 65° C. with a nucleic acid molecule selected from the group of SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:5, or a nucleotide sequence complementary to said isolated polynucleotide.
- 2. An isolated polynucleotide comprising the 1723 bp fragment of clone YCE174.
- 3. A vector comprising a polynucleotide of claim 1 operatively linked with a suitable regulatory element.
- 4. A vector according to claim 3, wherein the vector is an expression vector and the regulatory element is a promoter.
- 5. A cell comprising the vector of claim 3.
- 6. A process for producing a polypeptide of claim 1, comprising culturing a host cell of claim 15 under conditions suitable for the expression of said polypeptide and recovering the polypeptide.
- 7. An antibody immunospecific for the polypeptide of claim 1.
- 8. A method for screening for a compound which influences the activity of the polypeptide claim 1, the method comprising:
(a) contacting a preparation comprising a polypeptide of claim 1 with a compound; and (b) assessing whether the candidate compound results in a stimulation or inhibition of the activity of said polypeptide.
- 9. A method according to claim 8, wherein the preparation comprises a cell expressing and polypeptide.
- 10. A method according to claim 8, wherein the candidate compound is assessed in the presence of a suitable substrate for the polypeptide.
- 11. A method according to claim 8, wherein the candidate compound is mixed with a solution containing the polypeptide and a suitable substrate to form a mixture, an activity of the polypeptide in the mixture is measured and compared with the activity of the polypeptide in a control solution without the candidate compound.
- 12. A pharmaceutical composition comprising a compound selected from the group consisting of:
(a) a polypeptide according to claim 1;(b) a stimulant or inhibitor to the polypeptide; (c) an isolated polynucleotide encoding the polypeptide; and (d) a nucleic acid molecule that modulates the expression of the polynucleotide.
- 13. A method of diagnosing a disease or susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising one or more steps of:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and (b) comparing a level of expression of the polypeptide a sample derived from said subject with a standard base level.
Priority Claims (4)
Number |
Date |
Country |
Kind |
99203862.0 |
Nov 1999 |
EP |
|
1013616 |
Nov 1999 |
NL |
|
00201937.0 |
May 2000 |
EP |
|
1015356 |
May 2000 |
NL |
|
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of international patent application no. PCT/EP00/11532, filed Nov. 17, 2000, designating the United States of America, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on European patent application no. 99 20 3862.0, filed Nov. 19, 1999; Dutch patent application no. 1013616, filed Nov. 19, 1999; European application no. 00201937.0, filed May 31, 2001; and Dutch patent application no. 1015356, filed May 31, 2000.
Divisions (1)
|
Number |
Date |
Country |
Parent |
10147928 |
May 2002 |
US |
Child |
10870003 |
Jun 2004 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/EP00/11532 |
Nov 2000 |
US |
Child |
10147928 |
May 2002 |
US |